Campona Airmaster™

(Salmeterol / Fluticasone)

Prescribing Information can be FOUND HERE

Asthma

Campona Airmaster™ is indicated in the regular treatment of asthma where use of a combination product (long- acting β2 agonist and inhaled corticosteroid) is appropriate:

  • patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting β2 agonist or

  • patients already adequately controlled on both inhaled corticosteroid and long-acting β2 agonist

Note: Campona Airmaster™ 50 microgram /100 microgram strength is not appropriate in adults and children with severe asthma.

Campona Airmaster™ 50 microgram/500 microgram/ dose inhalation powder, pre-dispensed.123

Chronic Obstructive Pulmonary Disease (COPD)

Campona Airmaster™ is indicated for the symptomatic treatment of patients with COPD, with a FEV1 < 60 % predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.

*Only the 50/500mcg Campona strength is indicated for the treatment of COPD.3

50/100mcg

50/250mcg

50/500mcg*

Why Campona Airmaster™?

Explore More

References

By clicking the below links you will be leaving a Genesis Pharmaceutical website and entering a website that is not controlled by Genesis Pharmaceuticals.

1. Campona airmaster™ 50 micrograms / 100 micrograms / dose inhalation powder, pre-dispensed. Summary of product characteristics. Available here. (Accessed: 2 October 2023).

2. Campona airmaster™ 50 micrograms / 250 micrograms / dose inhalation powder, pre-dispensed. Summary of product characteristics. Available here. (Accessed: 2 October 2023).

3. Campona airmaster™ 50 micrograms / 500 micrograms / dose inhalation powder, pre-dispensed. Summary of product characteristics. Available here. (Accessed: 2 October 2023).

4. Medicinal forms fluticasone with salmeterol. NICE. Available here. (Accessed: 20 September 2023).

Adverse Events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Adverse events should also be reported to Activase Pharmaceuticals at eupvg@genreg.eu or 02072010421